Temperament and Character Profiles of Ankylosing Spondylitis Patients Compared With Major Depression Patients and Healthy Controls

Tönük, Şükrü Burak; Arısoy, Özden; Öztürk, Erhan Arif; Boztaş, Mehmet Hamid; Kaygusuz, Çiğdem Çifci; Sultanoğlu, Tuba Erdem

doi:10.1097/rhu.0000000000001510

Cited by 2 publications

(1 citation statement)

References 36 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 The inflammation and pain resulted in a spinal stiffness, a loss of spinal motility, sleep disturbance, and secondary anxiety and depression. 5 Inevitably, the sexual function of AS patients was impaired, as the previously mentioned physical and psychological adverse effects were the risk factors of sexual dysfunction. 6 However, the physical and anatomic impairments of AS surely claim most attention, while easily overlooking sexual function.…”

Section: Introductionmentioning

confidence: 99%

Erectile dysfunction in ankylosing spondylitis: a systematic review and meta-analysis

Zhang,

Wu,

Zhang

et al. 2023

Sexual Medicine

View full text Add to dashboard Cite

Background The prevalence of erectile dysfunction (ED) in ankylosing spondylitis (AS) patients was reported rarely and with small sample. Aim The study sought to explore the prevalence of ED in men with AS and to determine whether AS is a risk factor for ED. Methods A systematic search was conducted in the China National Knowledge Infrastructure, Wanfang, VIP Database, CBM, PubMed, Web of Science, and Cochrane Library. The search was restricted to the articles published up to October 2022. Assessment tools adapted for prevalence studies were used to evaluate the quality of cross-sectional studies, and the quality of case-control studies was assessed by Newcastle–Ottawa scale. The relative risk (RR) and the standard mean difference (SMD) were used to evaluate the association between AS and ED. The subgroup analyses were conducted to identify the resources of heterogeneity. The sensitivity analysis was performed to assess the stability of the pooled estimates. Data were analyzed and graphed using STATA 16.0. Outcomes The pooled prevalence of ED in AS patients was calculated and the RR and the SMD were used to evaluate the association between AS and ED. Results A total of 393 AS patients, enrolled in the 8 included studies, were assessed for the prevalence of ED. The pooled ED prevalence estimate was 44% (95% confidence interval [CI], 25% to 63%, P < .001) with the statistical heterogeneity (I2 = 95.1%, P < .001). After pooling the data for RR, the results showed that men with AS were at a significantly higher risk for ED when compared with the general population without AS (RR, 2.04; 95% CI, 1.28 to 3.25, P = .003; heterogeneity: I2 = 72.6%, P = .003). The pooled results of 5 studies, which provided the International Index of Erectile Function (IIEF) score, demonstrated that patients with AS had significantly lower values in the IIEF erectile function domain as compared with the healthy control subjects (SMD, −0.60; 95% CI, −0.80 to −0.41; P < .001; heterogeneity: I2 = 34.4%, P = .192). Additionally, the other domain of the IIEF also showed lower values when compared with the general population without AS (P < .05). Clinical Implications The present meta-analysis provides evidence of the management of ED in men with AS. Strengths and Limitations This is the first meta-analysis to provide the prevalence of ED in AS patients and to demonstrate that AS is a risk factor for ED. However, the results after pooling the included studies showed significant heterogeneity. Conclusion Our meta-analysis demonstrated the high prevalence of ED in men with AS and that AS is a potential risk factor for ED.

show abstract

Section: Introductionmentioning

confidence: 99%

Erectile dysfunction in ankylosing spondylitis: a systematic review and meta-analysis

Zhang,

Wu,

Zhang

et al. 2023

Sexual Medicine

View full text Add to dashboard Cite

show abstract

Evaluation of the efficacy of Tongdu Shujin Decoction combined with Adalimumab in the treatment of ankylosing spondylitis: A study protocol for a randomized controlled trial

Liu

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction Ankylosing spondylitis (AS) is a chronic inflammatory disease that typically affects the axial skeleton and entheses, and can lead to severe physical and psychological damage to patients. However, the current therapies have limitations.Methods and analysis Eighty-patients with AS will be recruited from the Rheumatology Department of the First Affiliated Hospital of the Henan University of Chinese Medicine. The participants will be randomly divided into the treatment and control groups at a 1:1 ratio. Subsequently, all subjects in the treatment group will receive 40 mg adalimumab administered subcutaneously every two weeks for 12 weeks, while patients in the control group will receive an extra dose of Tongdu Shujin Decoction (TDSJ) each day. The primary outcome will be determined by the change in the Ankylosing Spondylitis Disease Activity Score (ASDAS) from baseline to 12 weeks. The secondary outcomes include changes of serum inflammatory cytokines, interleukin-6 (IL-6), interleukin-17 (IL-17), Tumor necrosis factor alpha (TNF-α), changes of anxious depression-related scales, Hospital Anxiety and Depression Scale (HADS) and Patient Health Questionnaire-9 (PHQ-9) as well as changes of McGill Pain Questionnaire (MPQ) and Fatigue Severity Scale (FSS) in patients from baseline to 12 weeks.Ethics and dissemination The ethics committee of the First Affiliated Hospital of Henan University of Chinese Medicine has approved the study on April 27, 2023 (2023HL-116-02). The Chinese national authorities issued approval on 15 May 2023. The outcome of the study will be disseminated via peer-reviewed publications and at congresses.Trial registration number Chinese Clinical Trial Registry. ChiCTR2300071418. Registered on 15th May 2023. https://www.chictr.org.cn/showproj.html?proj=196506

show abstract

Temperament and Character Profiles of Ankylosing Spondylitis Patients Compared With Major Depression Patients and Healthy Controls

Cited by 2 publications

References 36 publications

Erectile dysfunction in ankylosing spondylitis: a systematic review and meta-analysis

Erectile dysfunction in ankylosing spondylitis: a systematic review and meta-analysis

Evaluation of the efficacy of Tongdu Shujin Decoction combined with Adalimumab in the treatment of ankylosing spondylitis: A study protocol for a randomized controlled trial

Contact Info

Product

Resources

About